Grundinformationen
- Standard-SMILES
CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C- InChIKey
DOMWKUIIPQCAJU-LJHIYBGHSA-N- Summenformel
- C27H40O4
- Durchschnittliche Molmasse
- 428,6 g/mol
- Monoisotopische Masse
- 428,29265976
Überblick
Hydroxyprogesterone caproate is a corticosteroid hormone.
Namen und Bezeichner
- Bevorzugter Name
- Hydroxyprogesterone Caproate
- IUPAC
- [(8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate
Namen und Synonyme
HYDROXYPROGESTERONE CAPROATE630-56-8DelalutinPrimolut DepotHydroxyprogesterone hexanoateHormofortSyngynonProluton DepotDepo-ProlutonTeralutilHylutinMakena
Weitere Namen anzeigen
Pharlon17alpha-Hydroxyprogesterone caproateProcyte depoNSC-1759217-alpha-hydroxy-progesterone caproate17-OHPC17alpha-Caproyloxypregn-4-ene-3,20-dione17-((1-Oxohexyl)oxy)pregn-4-ene-3,20-dione
Datenbank-Bezeichner
- CAS
630-56-8- PubChem CID
- 169870
- DTXSID
DTXSID6043915- ChEMBL
CHEMBL1200848- ChEBI
CHEBI:5812- UNII
- 276F2O42F5
- EC Number
- 211-138-8
- Nikkaji
- J6.891H
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 5,7
- Polarare Oberfläche (TPSA)
- 60,4 Ų
- H-Brücken-Donoren
- 0
- H-Brücken-Akzeptoren
- 4
- Frei drehbare Bindungen
- 7
- Schwere Atome
- 31
- Formalladung
- 0
- Komplexität
- 797
Experimentelle und physikochemische Eigenschaften
Drugs
Pharmaceuticals -> Listed in ZINC15
Pharmaceutical
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Animal DrugsPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point119-121
Collision Cross Section225.6 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID6043915]
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Danger
H360 (93.2%): May damage fertility or the unborn child [Danger Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 44 reports by companies from 7 notifications to the ECHA C&L Inventory.
Gefahrenhinweise
Regulatory InformationHydroxyprogesterone caproate: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Other Safety InformationIMAP assessments - Pregn-4-ene-3,20-dione, 17-[(1-oxohexyl)oxy]-: Environment tier I assessment
Hazard Classes and CategoriesRepr. 1B (93.2%)
Toxikologische Informationen
Carcinogen Classification2B, possibly carcinogenic to humans. (L135)
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Hydroxyprogesterone caproate
Ambiguous-DILI-concern
2
Warnings & precautions
DOI:10.1016/j.drudis.2016.02.015
Chemie und Industrie
Pharmakologische Informationen
Protein BindingHydroxyprogesterone caproate is extensively protein bound in the plasma.
PharmacodynamicsNo specific pharmacodynamic studies have been performed to assess hydroxyprogesterone caproate injections. However, the mechanism of action is likely related to increased interaction between progesterone and progesterone receptors.
Mechanism of Action
The mechanism by which progesterone prevents preterm birth is not well understood, but many pathways are likely involved. Progesterone plays a vital role in regulation of the female reproductive system and is important for successful implantation of the embryo and maintenance of pregnancy. It acts by binding to progesterone receptors in the uterus, ovaries, breasts and in the central nervous system. These receptors exist in 2 isoforms, PR-A and PR-B. Progesterone binding to these receptors ultimately leads to regulation of gene transcription. This results in an anti-inflammatory effect which blunts the proinflammatory state that occurs with initiation of labor, and maintains uterine queiscence by stabilizing progesterone acting on the myometrium.
Biological Half-LifeHalf-life = 16 days (±6 days).
Metabolism/MetabolitesThe main enzymes involved in metabolism of hydroxyprogesterone caproate are cytochrome P450 (CYP) 3A4 and to a lesser extent CYP3A5.
FDA Pharmacological Classification
HYDROXYPROGESTERONE CAPROATE
Progesterone Congeners [CS]; Progestin [EPC]
MeSH Pharmacological Classification
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.
Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.
Absorption, Distribution and Excretion
Absorption of 17-hydroxyprogesteron caproate is slow, occurring over a long period of time.
Following intramuscular injection, approximately 50% of hydroxyprogesterone caproate metabolites are eliminated in the feces, while approximately 30% of metabolites are eliminated in the urine.
Hydroxyprogesterone caproate has a high volume of distribution.
Clearance is highly variable from patient to patient.
Verwendung und Herstellung
Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Zugehörige Reaktionen
1
Verknüpfte Notizen
Wird geladen…